Insulet (NASDAQ:PODD) Cut to Market Perform at Leerink Partners

Insulet (NASDAQ:PODD) was downgraded by stock analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Thursday. They currently have a $145.00 price target on the medical instruments supplier’s stock. Leerink Partners’ target price indicates a potential upside of 8.81% from the stock’s current price.

Several other research firms also recently weighed in on PODD. Sanford C. Bernstein dropped their price objective on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Barclays decreased their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research report on Thursday, May 7th. Bank of America lowered their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Stifel Nicolaus dropped their price target on Insulet from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Finally, Benchmark reaffirmed a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Fifteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $212.58.

Insulet Stock Down 20.1%

PODD stock opened at $133.26 on Thursday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average price is $155.56 and its 200 day moving average price is $195.01. Insulet has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a market cap of $9.23 billion, a P/E ratio of 30.99, a P/E/G ratio of 1.16 and a beta of 1.10.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. During the same period last year, the company posted $1.17 earnings per share. The firm’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts expect that Insulet will post 6.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

A number of large investors have recently modified their holdings of PODD. State Street Corp grew its holdings in shares of Insulet by 2.1% during the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after purchasing an additional 65,317 shares during the period. Geode Capital Management LLC raised its holdings in Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after buying an additional 41,019 shares during the period. Invesco Ltd. lifted its position in Insulet by 10.5% during the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after buying an additional 141,167 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Finally, Norges Bank purchased a new stake in Insulet during the fourth quarter worth approximately $300,794,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q2 results exceeded expectations. Insulet reported adjusted earnings of $1.66 per share versus the $1.47 consensus estimate, while revenue rose 23.5% year over year to $801.7 million, topping expectations of $787.4 million. The company also highlighted continued growth in its Omnipod business. Insulet Beats Q2 Earnings and Revenue Estimates
• Neutral Sentiment: Management said the broader growth outlook remains intact, but Type 2 patient adoption is being reset. The earnings call indicated that some Type 2 diabetes users discontinued Omnipod before 90 days, creating uncertainty around near-term customer retention and future expansion. Insulet Earnings Call: Growth Intact Amid Type 2 Reset
• Negative Sentiment: Insulet lowered its outlook. Full-year 2026 revenue guidance was reduced to approximately $3.2 billion-$3.3 billion, below the roughly $3.3 billion analyst expectation. Third-quarter revenue guidance of $829.9 million-$844.0 million also trailed the $846.3 million consensus, reflecting slower U.S. insulin-pump sales. Insulet Cuts Sales Growth Forecast
• Negative Sentiment: Oppenheimer downgraded PODD from “outperform” to “market perform,” adding pressure after the guidance reduction and concerns about demand trends.
• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action. The lawsuit alleges that Insulet and certain executives made misleading statements about manufacturing quality and product safety before two Omnipod medical-device corrections. Investors purchased during the alleged class period may seek lead-plaintiff status by August 31, 2026. The allegations have not been proven, but the litigation adds reputational, legal and potential financial risk. Insulet Investor Alert

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.